The expression level and diagnostic value of microRNA-22 in HCC patients

References

• Lai EC, Lau WY. The continuing challenge of hepatic cancer in Asia. Surgeon. 2005;3(3):210–215.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–1127.
   PubMed Web of Science ®Google Scholar
• Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol. 2015;7(12):1632–1651.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Phillips D, Jain D, et al. Comparison of 5 immunohistochemical markers of hepatocellular differentiation for the diagnosis of hepatocellular carcinoma. Arch Pathol Lab Med. 2015;139:1028–1034.
   PubMed Web of Science ®Google Scholar
• Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev. 2004;18:504–511.
   PubMed Web of Science ®Google Scholar
• Gramantieri L, Fornari F, Callegari E, et al. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med. 2008;12(6a):2189–2204.
   PubMed Web of Science ®Google Scholar
• Li W, Xie L, He X, et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer. 2008;123(7):1616–1622.
   PubMed Web of Science ®Google Scholar
• Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361(15):1437–1447.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Fang JH, Yun JP, et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology. 2010;51:836–845.
   PubMed Web of Science ®Google Scholar
• Wan WN, Zhang YQ, Wang XM, et al. Down-regulated miR-22 as predictive biomarkers for prognosis of epithelial ovarian cancer. Diagn Pathol. 2014;9(1):178.
   PubMed Web of Science ®Google Scholar
• Poliseno L, Salmena L, Riccardi L, et al. Identification of the miR-106b∼25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal. 2010;3(117):ra29.
   PubMed Web of Science ®Google Scholar
• Xiong J, Yu D, Wei N, et al. An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. FEBS J. 2010;277(7):1684–1694.
   PubMed Web of Science ®Google Scholar
• Kawahigashi Y, Mishima T, Mizuguchi Y, et al. MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs. J Nippon Med Sch. 2009;76(4):188–197.
   PubMedGoogle Scholar
• Lionetti M, Agnelli L, Mosca L, et al. Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosom Cancer. 2009;48:521–531.
   PubMed Web of Science ®Google Scholar
• Ling B, Wang GX, Long G, et al. Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3. J Cancer Res Clin Oncol. 2012;138(8):1355–1361.
   PubMed Web of Science ®Google Scholar
• Li J, Liang S, Yu H, et al. An inhibitory effect of miR-22 on cell migration and invasion in ovarian cancer. Gynecol Oncol. 2010;119(3):543–548.
   PubMed Web of Science ®Google Scholar
• Yamakuchi M, Yagi S, Ito T, et al. MicroRNA-22 regulates hypoxia signaling in colon cancer cells. PLoS One. 2011;6(5):e2029.
   Web of Science ®Google Scholar
• Zhang J, Yang Y, Yang T, et al. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer. 2010;103(8):1215–1220.
   PubMed Web of Science ®Google Scholar
• Zhou L, He J, Zhang Y. MicroRNA-22 expression in hepatocellular carcinoma and its correlation with ezrin protein. J Int Med Res. 2013;41(4):1009–1016.
   PubMed Web of Science ®Google Scholar
• Huang X, Hollinger FB. Occult hepatitis B virus infection and hepatocellular carcinoma: a systematic review. J Viral Hepat. 2014;21(3):153–162.
   PubMed Web of Science ®Google Scholar
• Chan DL, Alzahrani NA, Morris DL, et al. Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(1):31–41.
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Zheng W, Hai J. MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis. Med Oncol. 2014;31(6):984.
   PubMed Web of Science ®Google Scholar
• Zhuang L, Zeng X, Yang Z, et al. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8(9):e61361.
   PubMed Web of Science ®Google Scholar
• Ren W, Qi X, Jia J, et al. Prevalence of hepatocellular carcinoma in Chinese Budd-Chiari syndrome patients: an extended systematic review using Chinese-language databases. Eur J Gastroenterol Hepatol. 2013;25:1241–1243.
   PubMed Web of Science ®Google Scholar
• Shen A, Zhang H, Tang C, et al. Systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm. J Gastroenterol Hepatol. 2013;28(5):793–800.
   PubMed Web of Science ®Google Scholar
• Yamanaka K, Petrulionis M, Lin S, et al. Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma – systematic review and meta-analysis. Cancer Med. 2013;2(6):862–871.
   PubMed Web of Science ®Google Scholar
• Yin Z, Fan X, Ye H, et al. Short- and long-term outcomes after laparoscopic and open hepatectomy for hepatocellular carcinoma: a global systematic review and meta-analysis. Ann Surg Oncol. 2013;20(4):1203–1215.
   PubMed Web of Science ®Google Scholar
• Zavaglia C, Airoldi A, Mancuso A, et al. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. Eur J Gastroenterol Hepatol. 2013;25:180–186.
   PubMed Web of Science ®Google Scholar
• Wang WB, Li FJ, Zhang Y, et al. Reduced expression of miR-22 in gastric cancer is related to clinicopathologic characteristics or patient prognosis. Diagn Pathol. 2013;8(1):102.
   PubMedGoogle Scholar
• Liu L, Jiang Y, Zhang H, et al. miR-22 functions as a micro-oncogene in transformed human bronchial epithelial cells induced by anti-benzo[a]pyrene-7,8-diol-9,10-epoxide. Toxicol In Vitro. 2010;24(4):1168–1175.
   PubMed Web of Science ®Google Scholar